Akrimax Pharmaceuticals, LLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akrimax Pharmaceuticals, LLC
Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.
FDA sends untitled letter to Citius Pharmaceuticals and licensee Akrimax for not including any risk information on webpage for weight loss product; Akrimax received a similar citation in March for a Tirosint Facebook page.
Office of Prescription Drug Promotion also expresses concern that Facebook page for hypothyroidism drug Tirosint fails to include limits on the indication.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
- Specialty Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.